Lv11
80 积分 2026-01-08 加入
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
25天前
已完结
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation
25天前
已完结
Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians
1个月前
已完结
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
1个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
2个月前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
2个月前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
2个月前
已完结
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
2个月前
已完结
Paraneoplastic syndromes review: The great forgotten ones
2个月前
已完结
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
3个月前
已完结
皖公网安备34019202002308
